Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen-Cilag changes wholesaling arrangements in the UK

This article was originally published in Scrip

Executive Summary

Janssen-Cilag(Johnson & Johnson) is the latest pharmaceutical company to change its wholesaling arrangements in the UK. It will reduce the number of full-line wholesalers that it uses toAAH Pharmaceuticals, Phoenix Healthcare Distribution andUnichem. It will, however, retain the standard wholesaling model for its business. The new arrangements apply to the mainland of Great Britain, and come into effect in January. A number of other UK companies have also limited the number of wholesalers that they deal with over the past few years, and several have altered their business practices so that distributors act as agents rather than as conventional wholesalers.

You may also be interested in...



Rare Genetic Epilepsy Responsive To Marinus's Ganaxolone

Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.

Pipeline Watch: Phase III Starts For Fenebrutinib, Chikungunya Vaccine, Fruquintinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Israel VC Backs MiNA's Novel SaRNAs In Cancer, And Add-On Therapy Areas

Small activating RNA research being pioneered by London, UK-based MiNA Therapeutics has attracted $30m in a series A funding, led by a tech billionaire-backed life sciences VC fund.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel